COVID-19: How Orbis International is managing operations

Article

Danny Haddad, MD, chief of program at Orbis International, shares an update on how the company's operations have shifted during the coronavirus pandemic, as well as the record-breaking impact on one of its telehealth platforms.
 


See more coronavirus coverage here

 

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
EYLEA 8mg in focus: Key learnings from the pivotal trials
EYLEA 8mg in focus: Key learnings from the pivotal trials
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
Early intervention is crucial for long-term outcomes in paediatric gene therapy
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Robert Ang, MD, explains why a small-aperture IOL is "not a niche product"
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
ARVO 2025: Ocular and systemic mitochondrial diseases may be key to dementia diagnosis
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
ARVO 2025: Alfredo Sadun, MD, PhD, says "later is better" for some LHON interventions
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Nitish Mehta, MD, provides real-world insights from aflibercept 8 mg for treatment-naive diabetic macular oedema
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
ARVO 2025: Anat Loewenstein, MD, and colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
Sheng Lim, MD, FRCOphth, brings data from the CONCEPT study to the ASCRS meeting
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
A panel discussion on extended treatment intervals in retinal therapy breaks the mold at COPHy 2025
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
How embracing opposition sends clinicians home from COPHy with more useful takeaways
Related Content
The river Neckar, as seen from historic Heidelberg, Germany. ISS International Spectralis Symposium concept image. Image credit: ©Dreadlock – stock.adobe.com

Full list of topics at the upcoming International SPECTRALIS Symposium

Hattie Hayes
June 9th 2025
Article

More than 35 lectures across seven topics, plus a keynote address, will be featured during the meeting

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

The Belém Tower (Torre de Belém) in Lisbon, Portugal. Concept image for ophthalmology conference, European Society of Ophthalmology SOE Congress 2025 meeting program and schedule. Image credit: ©PhotosbyPatrick – stock.adobe.com

Keynote lectures and YO sessions at the 2025 SOE Congress

Hattie Hayes
June 7th 2025
Article

Special programming for young ophthalmologists will be hosted in the YO lounge

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

The Agência de vigilância Sanitária (ANVISA) in Brazil. Concept image for pharmaceutical approval, Lucentis ranibizumab biosimilar ranivisio FYB201. Image credit: ©Rmcarvalhobsb – stock.adobe.com

Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

Lynda Charters
June 5th 2025
Article

The biopharmaceutical is the first biosimilar to ranibizumab (Genentech Inc.) approved in Brazil

The European Commission building in Brussels, Belgium, with EU flags on view out front. Concept image for EC pharmaceutical ophthalmic drug approval. Image credit: ©xbrchx – stock.adobe.com

European Commission approves low-dose atropine eye drop Ryjunea, Santen announces

Hattie Hayes
June 5th 2025
Article

The 0.1 mg/ml atropine eye drop for paediatric myopia is licensed from Sydnexis, Inc.

© 2025 MJH Life Sciences

All rights reserved.